CompletedNot Applicable

New Concepts in Diabetic Macular Edema (DME)

150 participantsStarted 2014-09-10

Plain-language summary

Intravitreal ranibizumab injection procedure is simple and effective. In management of chronic DME there is no clear anatomical endpoint. Visual stability is the primary aim. Argon focal laser therapy can be the safe second choice. The combined therapy is successful and practical for chronic DME patients.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * focal maculopathy * diffuse macular edema * diffuse macular edema with ischemic changes Exclusion Criteria: * ischemic maculopathy that was associated with grades of non-proliferative changes, or capillary drop out zones presented in the periphery of the macula * patients with history of stroke or transient ischemic attack * hypersensitivity to ranibizumab or any component of the ranibizumab formulation * uncontrolled glaucoma in either eye (intraocular pressure \[IOP\] \>24 mmHg with medication) * evidence of vitreomacular traction (in either eye) * active proliferative diabetic retinopathy (study eye)

What they're measuring

visual acuity letter score

Timeframe: one-year follow up

central subfield thickness (CST)

Timeframe: one-year follow up

Trial details

NCT IDNCT04186702

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-10-01

View on ClinicalTrials.gov More Diabetes Mellitus, With Complications trials